Varex Imaging stock
VREXNASDAQVarex Imaging Corporation, HealthcareISIN US92214X1063
53Score 53 out of 100, Neutral
Price and trend
70 / 100
Price history
+48% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 33% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 1.0% below its 52-week high. Largest decline in 10 years: 84% (February 2018 to May 2025).
Chart figures for advanced users
- SMA 50$18.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.32
- The lowest closing price of the last twelve months.
- Resistance$18.58
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Varex Imaging Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $780.9M, is number 66 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $844.6M (up 4.1% year on year) and a loss of $70.3M.
- MEQIRI Score 53 out of 100 (Neutral): rank 364 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $17.73, with the price 4% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Margin fallingOperating margin −3.3%, average of the prior years 8.6% (to 2024).Profitability 39
- Negative free cash flowFree cash flow −$20.2M over the last 12 months.Fundamentals 46
- Volatile share priceVolatility 63% a year over the last 12 months.Stability 48
Its standout strengths are momentum and technical analysis, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $11.82 and expensive above $35.47 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $15.17, at 8.9% it would be $21.33.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 3 Jul 2026, revenue rose 5.3% on the twelve months before. Revenue has stayed largely stable since 2013.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 34%, operating −3%, net −8%. Last 12 months: net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Nov 2026in 5 days
- Last reported
- 10 Aug 2026EPS reported $0.31 (expected $0.21)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.070.0%
- Revenue
- $900.27M0.0%
- Earnings per share
- $1.400.0%
- Revenue
- $965M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −19.2%The company moves to annual guidance; second half revenue is expected to be up about 3% from the prior year period.
“For the second half of fiscal 2026, we expect revenue to be up approximately 3% compared to the same period of fiscal 2025.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $2.55M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Varex Imaging
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- OrthoPediatricsKIDS $879.14M47
- MedCapMCAP.ST $828.57M76
- Beta BionicsBBNX $801.27M47
- InModeINMD $790.08M72
- Delcath SystemsDCTH $757.34M64
- Cytek BiosciencesCTKB $753.32M47
- BioventusBVS $752.53M61
- Synektik Spólka AkcyjnaSNT.WA $709.44M77
ETFs that hold Varex Imaging
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Invesco Defence Innovation UCITS ETF AccumUSDIVDF | 1.12% | 0.35% | €134.79M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 3 Oct 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.